DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

Information source: Charleston Laboratories, Inc
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pain; Nausea; Vomiting

Intervention: CL-108 (Drug); Placebo (Drug); Norco (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: John Ameling

Overall contact:
Bernard P Schachtel, MD, Email: BSchachtel@charlestonlabs.com

Summary

The objectives of this study are to compare the occurrence and severity of opioid-induced nausea and vomiting (OINV) associated with CL-108 to Norco®, and to demonstrate the efficacy of CL-108 when compared to placebo for the relief of moderate to severe pain In patients with moderate to severe pain following bunionectomy (osteotomy with fixation of the head of the first metatarsal bone).

Clinical Details

Official title: A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose, Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Pain and Opioid-Induced Nausea and Vomiting (OINV)

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome:

The occurrence of opioid-induced nausea and vomiting (OINV) as assessed by an OINV questionnaire comparing CL-108 to Norco® over 48 hours.

The relief of moderate to severe pain, assessed by visual analog pain intensity scale, comparing CL-108 to placebo over 48 hours (SPID48).

Secondary outcome:

The severity of opioid-induced nausea, comparing CL-108 to Norco® over 48 hours

The occurrence of vomiting, comparing CL-108 to Norco® over 48 hours

The use of anti-emetics, comparing CL-108 to Norco® over 48 hours.

Incidence of post-discharge nausea and vomiting (PDNV), comparing CL-108 to placebo over days 3-5

The relief of post-operative nausea and vomiting (PONV), comparing CL-108 to placebo over 48 hours

The relief of severe pain, comparing CL-108 to Norco® over 48 hours, i.e., summed pain intensity differences over 48 hours (SPID48)

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

INCLUSION CRITERIA

- Informed Consent: Signed consent obtained at screening prior to any procedures being

performed.

- Gender: Male or non-pregnant and non-lactating female. A female of child-bearing

potential is eligible to participate in this study if she has a negative urine pregnancy test and is using an acceptable method of birth control (i. e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterilization)

- Age: 18 years or older

- OINV Status: At risk of OINV on the Nausea Prone Questionnaire (NPQ)

- Foot Condition: Surgical extraction of a unilateral first metatarsal bunion confirmed

by foot x-ray (assessed by surgeon prior to surgery)

- Pain Severity: Presence of moderate or severe pain (i. e., ≥ 4 on the baseline

numerical pain intensity rating scale [PI-NRS])

- Pain Confirm: Rating ≥ 50 mm on the baseline visual analog pain intensity scale

(PI-VAS)

- Diary Completion: Be willing and able to record safety and efficacy information in

the In-patient and Outpatient Diaries

- Safe Transportation: Patient must have arrangements for transportation home from the

research center accompanied by a responsible adult EXLUSION CRITERIA

- Medical Condition: Presence of a serious medical condition (e. g., poorly controlled

hypertension or diabetes, neurological disease including Parkinson's or other condition associated with a movement disorder, significantly impaired cardiac, renal, hepatic, respiratory, or thyroid function)

- Infection: Acute local infection at the time of surgery that could confound

post-surgical evaluation.

- Drug Allergy: History of hypersensitivity or allergy to an opioid drug such as

hydrocodone, promethazine, acetaminophen, ondansetron, NSAID (such as ibuprofen, including aspirin) or ketorolac or history of a dystonic/dyskinetic reaction to prior anti-emetic or anti-psychotic medication

- Contraindicated Drugs: Use (within 24 hours of the surgical procedure) of any

confounding prescription or non-prescription drug (e. g., analgesic, anti-emetic, sedating antihistamine, sedative, alcohol, CNS/psychotropic agent, including sleep aides, benzodiazepines, performance/attention enhancers, marijuana, anti-depressants) or any drug contraindicated with hydrocodone, acetaminophen, or promethazine (except for pre-op medications). Antibiotic prophylaxis for endocarditis (except if known to cause nausea) and ASA 62. 5 mg for cardiovascular prophylaxis are permitted during the study.

- History of drug or alcohol abuse

- Caffeine Use: Ingestion of any caffeine-containing beverage or chocolate since

mid-night before the operation

- Investigation Drug Use: Use of an investigational drug within the past 30 days

- Participated in Study: Previous participation in this study

- Pregnancy, Lactation: Women who are pregnant or lactating

- Participant Relation: Employee at the research center or of Charleston Laboratories

or relative of the Principal Investigator, Sub-Investigators, or research staff who is directly involved in this study

Locations and Contacts

Bernard P Schachtel, MD, Email: BSchachtel@charlestonlabs.com

University of Pennsylvania, Philadelphia, Pennsylvania 19104-6030, United States; Recruiting
Bernbard P Schachtel, MD
Bernard P Schactel, MD, Principal Investigator
Additional Information

Charleston Website

Starting date: October 2014
Last updated: June 2, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017